Gland Pharma (NSE:GLAND) COGS-to-Revenue : 0.39 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Gland Pharma COGS-to-Revenue?

Gland Pharma's Cost of Goods Sold for the three months ended in Mar. 2024 was ₹5,994 Mil. Its Revenue for the three months ended in Mar. 2024 was ₹15,375 Mil.

Gland Pharma's COGS to Revenue for the three months ended in Mar. 2024 was 0.39.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Gland Pharma's Gross Margin % for the three months ended in Mar. 2024 was 61.01%.

Gland Pharma COGS-to-Revenue Historical Data

The historical data trend for Gland Pharma's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gland Pharma COGS-to-Revenue Chart

Gland Pharma Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

COGS-to-Revenue

Get a 7-Day Free Trial

0.43

0.44

0.48

0.46

0.38

Gland Pharma Quarterly Data
	Mar19	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.46	0.37	0.38	0.39	0.39

Gland Pharma COGS-to-Revenue Calculation

Gland Pharma's COGS to Revenue for the fiscal year that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	21730.88	/	56647.22
	=	0.38

Gland Pharma's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	5993.82	/	15374.5
	=	0.39

Gland Pharma (NSE:GLAND) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Gland Pharma's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	5993.82 / 15374.5
	=	61.01 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Gland Pharma COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Gland Pharma's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Gland Pharma (NSE:GLAND) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gland Pharma Ltd (NSE:GLAND) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

543245:India

Address

Plot No. 11 and 84, TSIIC Phase: IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, TG, IND, 502307

Website

https://www.glandpharma.com

Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Further, the group is involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.

Gland Pharma (NSE:GLAND) Headlines

No Headlines